Additive effect of ACE inhibition and Angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 14, Issue 4, 2003, Pages 992-999

  Jacobsen, Peter ^a   Andersen, Steen ^a   Jensen, Berit R ^a   Parving, Hans Henrik ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0037378751     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000054495.96193.BF     Document Type: Article

References (48)

1. Rossing P: Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med 15: 900-919, 1998
2. Parving HH, Osterby R, Ritz E: Diabetic nephropathy. In: The Kidney, 6 ed., edited by Brenner BM, Philadelphia, WB Saunders, 2000, pp 1731-1773
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
4. de Jong PE, Navis G, de Zeeuw D: Renoprotective therapy: titration against urinary protein excretion. Lancet 354: 352-353, 1999
5. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321: 1440-1444, 2000
6. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 17: 1019-1024, 2002
7. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1: 1175-1179, 1983
8. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, Kastrup J, Lefebvre P, Mathiesen ER, Feldt-Rasmussen B: Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest 9: 85-95, 1985
9. Brochner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30: 271-274, 1972
10. Brochner-Mortensen J, Rodbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36: 35-43, 1976
11. Brochner-Mortensen J, Rodbro P: Comparison between total and renal plasma clearance of [51Cr] EDTA. Scand J Clin Lab Invest 36: 247-249, 1976
12. Kappelgaard AM, Nielsen MD, Giese J: Measurement of angiotensin II in human plasma: Technical modifications and practical experience. Clin Chim Acta 67: 299-306, 1976
13. Deinum J, Derkx FH, Schalekamp MA: Improved immunoradiometric assay for plasma renin. Clin Chem 45: 847-854, 1999
14. Pinhero JC, Bates DM: Mixed-Effects Models in S and S-PLUS J, New York, Springer, 2000
15. Altman D: Clinical trials. In: Practical Statistics for Medical Research, 1 ed., edited by Altman G, London, Chapman & Hall/CRC, 1991, pp 440-474
16. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH: Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47: 1726-1731, 1995
17. Vanhoutte PM: Endothelium and control of vascular function. State of the Art lecture. Hypertension 13: 658-667, 1989
18. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 32: 387-392, 1998
19. Nussberger J, Brunner DB, Waeber B, Brunner HR: Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens Suppl 3: S269-S270, 1985
20. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 100: 1047-1058, 1997
21. Cao Z, Kelly DJ, Cox A, Casley D, Forbes JM, Martinello P, Dean R, Gilbert RE, Cooper ME: Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 58: 2437-2451, 2000
22. Cao Z, Bonnet F, Candido R, Nesteroff SP, Burns WC, Kawachi H, Shimizu F, Carey RM, De Gasparo M, Cooper ME: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 13: 1773-1787, 2002
23. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB: Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 39: 159-164, 2002
24. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 9: 224-230, 1998
25. Cao Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ, Gilbert RE: Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 36: 561-568, 2000
26. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind crossover study. Diabetes Care 25: 95-100, 2002
27. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18: 89-95, 2000
28. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38: 18-25, 2001
29. Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 20: 125-130, 2002
30. Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 17: 597-601, 2002
31. Nakao N, Yoshimura A, Morita H, Inui K, Takada M, Kayano T, Ideura T: Combination therapy of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease: A randomized, controlled trial in Japan (COOPERATE). Lancet 2002, in press
32. Muirhead N, Feagan B, Mahon J, Lewanczuk R, Wilson Rodger N, Botteri F, Oddou-Stock P, Pecher E, Cheung R: The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial. Curr Thera Res 60: 650-660, 2002
33. Lijnen P, Fagard R, Staessen J, Verschueren LJ, Amery A: Dose response in captopril therapy of hypertension. Clin Pharmacol Ther 28: 310-315, 1980
34. Gomez HJ, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, Chrysant SG, Gradman AH, Leon AS, MacCarthy EP: Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 28: 415-420, 1989
35. Whalen JJ: Definition of the effective dose of the convertingenzyme inhibitor benazepril. Am Heart J 117: 728-734, 1989
36. Eber B, Brussee H, Rotman B, Kramer R, Klein W: Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension. Angiology 43: 482-489, 1992
37. Pool JL, Glazer R, Chiang YT, Gatlin M: Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 13: 275-281, 1999
38. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59: 2282-2289, 2001
39. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH: Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17: 1413-1418, 2002
40. Gibbs CR, Beevers DG, Lip GY: The management of hypertensive disease in black patients. QJM 92: 187-192, 1999
41. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344: 1351-1357, 2001
42. Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving H-H: Dose-dependent reduction of proteinuria by losartan does not require reduction of blood pressure [Abstract]. J Am Soc Nephrol 13: 265A, 2002
43. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE: Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 16: 771-775, 2001
44. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl T, Parving H-H: Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2002, in press
45. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int. 45: 861-867, 1994
46. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57: 601-606, 2000
47. Buter H, van Tol A, Navis GJ, Scheek LM, de Jong PE, de Zeeuw D, Dullaart RP: Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer. Diabet Med 17: 550-552, 2000
48. Andersen S, Tank JE, Brenner BM: Renal and Systemic Manifestations of Glomerular Disease. In: The Kidney, 6 ed, edited by Brenner BM, Philadelphia, WB Saunders, 2000, pp 1871-1900